Clinical Trials Insight: 700016406
Phase of Trial: Phase II
Latest Information Update: 19 Oct 2009
At a glance
- Drugs TRU 015 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Emergent BioSolutions
- 19 Oct 2009 Results from the open-label re-treatment phase of the study reported in a Trubion Pharmaceuticals media release.
- 18 May 2009 Results from the re-treatment portion will be presented at the 2009 European League Against Rheumatism (EULAR) conference on June 11, reported by Trubion Pharmaceuticals.
- 11 Sep 2007 Preliminary results have been reported.